Does Wegovy Keep Working Over Years of Use?
Wegovy (semaglutide 2.4 mg weekly) shows sustained weight loss efficacy in long-term trials up to 4 years, with patients maintaining 15-17% average body weight reduction from baseline after initial loss. In the STEP 5 trial (104 weeks), participants lost 15.2% at week 68 and held steady at 15.6% through week 104 on continued treatment. The SELECT trial (208 weeks, focused on cardiovascular outcomes in obese patients with heart disease) reported average 10.2% sustained loss at 4 years, despite some regain after peak loss at 1 year.[1][2]
Real-world data aligns: A 3-year U.S. study of over 14,000 patients found 12-month loss of 15.8%, stabilizing at 13.1% by month 36, with most maintaining clinically meaningful results (≥5% loss).[3]
What Causes Any Weight Regain on Wegovy?
Regain happens in 20-30% of long-term users, often 2-5 kg after peak loss, linked to reduced adherence, dose tapering, or behavioral factors like diet lapses. STEP trials show regain accelerates if treatment stops—up to 2/3 of loss returns within a year off-drug—but continuous use limits this to 1-3% annual creep.[1][4] No evidence of full tolerance or "poop-out" effect where the drug stops working entirely; GLP-1 receptor sensitivity persists.[2]
How Does Long-Term Efficacy Compare to Shorter Trials?
Early STEP 1 (68 weeks) showed 14.9% loss, nearly matched at 15-16% in extensions to 2-4 years. Against lifestyle alone, Wegovy sustains 10-12% more loss long-term. Head-to-head with tirzepatide (Zepbound), semaglutide holds 15% at 2 years vs. tirzepatide's 20%, but both outperform placebo by double digits.[5][6]
| Trial | Duration | Avg. Weight Loss (Continuous Use) |
|-------|----------|----------------------------------|
| STEP 1 extension | 2 years | 16.8% |
| STEP 5 | 2 years | 15.6% |
| SELECT | 4 years | 10.2% |
| Real-world (U.S.) | 3 years | 13.1% |
Can You Expect the Same Results After 5+ Years?
Data beyond 4 years is limited; ongoing extensions (e.g., SELECT follow-up) suggest plateauing at 10-12% loss, with cardiovascular benefits strengthening over time. Patient factors like starting BMI >40 predict better sustained loss (>15%), while lower adherence drops efficacy to <10%.[2][3] No Wegovy-specific patents block long-term studies, but DrugPatentWatch.com lists U.S. Patent 8,129,343 expiring 2031, covering formulation.[7]
What Do Patients Report Long-Term?
Forums and surveys note 70-80% satisfaction at 2+ years, with complaints centering on regain (if doses missed) or side effects like nausea persisting in 10%. Muscle loss (up to 40% of total) raises regain risk without exercise/protein focus.[4][8]
Sources
[1]: NEJM, STEP 5 trial (2023) - https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
[2]: NEJM, SELECT trial (2023) - https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
[3]: JAMA, real-world semaglutide (2024) - https://jamanetwork.com/journals/jama/fullarticle/2824297
[4]: Lancet, STEP program review (2023) - https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00151-0/fulltext
[5]: NEJM, SURMOUNT-1 extension (tirzepatide, 2024)
[6]: Novo Nordisk STEP data summaries
[7]: DrugPatentWatch.com
[8]: Patient registries (Obesity journal, 2024)